• Elutia agreed to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million.
• Consideration includes $8 million cash at closing, with up to $3 million tied to technology transfer and commercial milestones over 18 months.
• Closing is expected in the second half of 2026, subject to customary closing conditions.
• Divestiture is set to sharpen focus on NXT-41x, targeting a 2027 commercial launch in U.S. plastic and reconstructive surgery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-085061), on July 20, 2026, and is solely responsible for the information contained therein.